Business
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community. The new initiative expands Serina’s direct channels of communication to provid
About this update from Serina Therapeutics, Inc.
[{"type":"image","alt":"Serina Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Serina Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/339c0b6f27c396eb444a95862a9f2125"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_rHPxM0Wn47pB..RwGicrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/339c0b6f27c396eb444a95862a9f2125","width":300,"height":88}},"lazy":false},{"type":"text","content":"HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community.","length":421,"tagName":"p"},{"type":"text","content":"The new initiative expands Serina’s direct channels of communication to provide stakeholders with clear, accessible information on the Company’s programs, regulatory progress, and scientific advances. The platform will feature regular digital updates, educational resources, multimedia content, and expert commentary from company leadership and scientific advisors.","length":365,"tagName":"p"},{"type":"text","content":"“At Serina, we believe leadership in biotechnology requires not only advancing innovative science but also communicating that progress with clarity and transparency,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “As we prepare to initiate the planned trial of SER-252 in Parkinson’s disease, this new communications platform will serve as a vital resource for patients, clinicians, investors, and the broader scientific community. By providing timely updates and expert perspectives, we are ensuring that all stakeholders can follow our journey as we work to bring meaningful new treatment options to people living with Parkinson’s disease and other serious conditions.”","length":692,"tagName":"p"},{"type":"text","content":"As part of the initiative, Serina plans to provide:","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Program and clinical updates delivered through...